Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Nov 22;623(7989):1034–1043. doi: 10.1038/s41586-023-06749-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Extended Data Fig. 8 — a, GSEA of upregulated MYC targets V1 (upper) and MYC target V2 (lower) in siNTC with TVA treatment compared to siCreb1 with TVA treatment. NES, normalized enrichment score. b, Ebi3, Foxo4, Bcl6, Ilf2, Tbx21, IL18, and Creb1 knockdown efficiency checked by RT-PCR (n = 3). c, TVA-Creb1 target genes validation: Log2 fold changes of IL-2 (left), TNF-α (middle), and IFN-γ (right) after TVA treatment in CD8⁺ T cells with individually transient knockdown of Creb1, Il18 (n = 6), Tbx21, Ilf2, Bcl6, Foxo4, and Ebi3 (n = 3). d, Gpr40, Gpr41, Gpr120, Gpr84, Gpr119, and Gpr43 knockdown efficiency checked by RT-PCR (n = 4). e, Gpr43 knockdown efficiency in CD8⁺ T cells was checked by RT-PCR (left) (n = 6). Effects of Gpr43 transient knockdown on cAMP (middle left), p-CREB (middle right), and p-STAT1 (right) levels in mouse CD8⁺ T cells treated with or without TVA were shown (n = 3). f, Effects of Gpr43 transient knockdown on TNF-α (left) and IFN-γ (right) levels in mouse CD8⁺ T cells treated with or without TVA (n = 3). g, Gpr43 knockdown efficiency in OT-I cells was checked by RT-PCR (left). Effect of Gpr43 transient knockdown on TNF-α level (right) in OT-I cells treated with or without TVA was shown (n = 3). h, Knockout efficiency of Gpr43 in Cas9;OT-I cells was checked by RT-PCR (upper left) (n = 4). Effects of individually knockout of Gpr43 with three sgRNAs on p-CREB level (upper right) and apoptosis (lower) in mouse Cas9;OT-I cells treated with or without TVA were shown (n = 3). i, Relative Gpr43 mRNA level (n = 6) and protein level (n = 3) in CD8⁺ T cells and CD4⁺ T cells with or without anti-CD3/CD28 stimulation. Data are mean ± SD (b-i). Nominal P values were adjusted by the Benjamini–Hochberg method (a), Student’s two-sided unpaired t test (b-i).

Source Data